Results 21 to 30 of about 10,598 (216)

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer [PDF]

JNCI: Journal of the National Cancer Institute, 2018
ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers. Pioneer cases of metastatic colorectal cancer (mCRC) patients bearing rearrangements who benefited from anti-ALK, ROS, and TrkA-B-C therapies have been reported previously.
Sun, James, Cremolini, Chiara, Tebbutt, Niall, Murphy, Danielle, Schrock, Alexa B, Hechtman, Jaclyn F, Christiansen, Jason, Novara, Luca, Tejpar, Sabine, Antoniotti, Carlotta, Fucà, Giovanni, Berenato, Rosa, Pietrantonio, Filippo, Di Nicolantonio, Federica, Chen, Marissa, Sartore-Bianchi, Andrea, Morano, Federica, Min, Bosun, Lee, Jeeyun, Kim, Seung Tae, Stephens, Philip J   +20 more
core   +7 more sources

NTRK expression and its clinical significance in pancreatic neuroendocrine tumors

Discover Oncology
Background The neurotrophic TRK family, which includes NTRK1, 2, and 3, could be the oncogenic driving force in various cancers, when they undergo fusion mutations with other genes and form a chimeric oncoprotein.
Pingping Yan, Xiaoqin Dai, Fenfen Zhang, Yu Dong, Huijuan Shi, Anjia Han   +5 more
doaj   +2 more sources

NTRK fusion in Japanese colorectal adenocarcinomas [PDF]

Scientific Reports, 2021
AbstractNTRK fusion-positive tumors are known to be highly sensitive to TRK inhibitors, such as larotrectinib and entrectinib. Therefore, identification of patients who can potentially benefit from these inhibitors is important; however, the frequency of NTRK fusions in Japanese patients with colorectal cancer (CRC) is unknown.
Yuya Yamashiro, Taisei Kurihara, Takuo Hayashi, Yoshiyuki Suehara, Takashi Yao, Shunsuke Kato, Tsuyoshi Saito   +6 more
openaire   +7 more sources

A Case of Primary Intramedullary Infantile Fibrosarcoma With an RBPMS::NTRK3 Fusion and Response to Larotrectinib. [PDF]

Neuropathol Appl Neurobiol
We report a case of primary intramedullary infantile fibrosarcoma (IFS) in a 4‐week‐old infant with rapidly progressive cervical myelopathy. Histology showed a spindle cell tumour with diffuse S100 and pan‐TRK expression. RNA sequencing identified an RBPMS::NTRK3 fusion.
Le Quang M, Tandonnet J, Truffaux N, Vanhersecke L, Delmas J, Durouchoux A, Bochaton D, Tauziède-Espariat A, Chotard G.   +8 more
europepmc   +2 more sources

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions [PDF]

Modern Pathology, 2021
Fusions involving NTRK1, NTRK2, and NTRK3 are oncogenic drivers occurring in a spectrum of mesenchymal neoplasms ranging from benign to highly malignant tumors. To gain further insights into the staining profile with the pan-TRK assay, we analyzed a large number of soft tissue sarcomas and correlated our findings with molecular testing.
Iva Brčić, Theresa Maria Godschachner, Marko Bergovec, Jasminka Igrec, Holger Till, Herwig Lackner, Susanne Scheipl, Karl Kashofer, Thomas Brodowicz, Andreas Leithner, Joanna Szkandera, Bernadette Liegl-Atzwanger   +11 more
openaire   +2 more sources

Adult Sarcomas with NTRK Fusions: Clinicopathologic and Genomic Heterogeneity. [PDF]

Cancers (Basel)
Background: NTRK gene fusions are established oncogenic drivers in a diverse spectrum of mesenchymal neoplasms. Although classically described in pediatric entities, NTRK-rearranged sarcomas also occur in adults, where their clinicopathologic features ...
Schwartz M, Sweeney K, Smith SC, Angara K, Reynolds C, Pappo AS, Elliott A, Oberley MJ, Evans MG, Bahrami A.   +9 more
europepmc   +2 more sources

Unusual presentation of lipofibromatosis-like neural tumor in an adult: A case report

Saudi Journal of Medicine and Medical Sciences, 2021
Lipofibromatosis-like neural tumor (LPF-NT) is a rare variant of lipofibromatosis. Standard lipofibromatosis tumors show a predilection for the distal extremities of male children or young adults and are typically painless, slow-growing, subcutaneous or ...
Muhammad Samsoor Zarak, Taylor Sliker, Tiffany Javadi, Asad Ullah, Saleh G Heneidi, Paul Biddinger, Natasha M Savage, Kelly Homlar, Joe Clarence, Joseph White   +9 more
doaj   +1 more source

NTRK insights: best practices for pathologists [PDF]

Modern Pathology, 2022
Since the discovery of an oncogenic tropomyosin-receptor kinase (TRK) fusion protein in the early 1980s, our understanding of neurotrophic tropomyosin-receptor kinase (NTRK) fusions, their unique patterns of frequency in different tumor types, and methods to detect them have grown in scope and depth. Identification of these molecular alterations in the
openaire   +2 more sources

Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project

Cancer Treatment and Research Communications, 2022
Introduction: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. Limited data exist on the overall survival (OS) of patients with tumors with NTRK gene fusions and on the co-occurrence of NTRK fusions ...
John Bridgewater, Xiaolong Jiao, Mounika Parimi, Clare Flach, Jeran Stratford, Atanas Kamburov, Arndt A. Schmitz, Jihong Zong, John A. Reeves, Karen Keating, Amanda Bruno, Marc Fellous, Mariana Buongermino Pereira, Lyudmila Bazhenova   +13 more
doaj   +1 more source

Primary and Metastatic Melanoma With NTRK Fusions [PDF]

American Journal of Surgical Pathology, 2018
A number of oncogenic driver mutations have been identified in melanocytic nevi and melanoma, but translocations also play a role in tumorigenesis and provide potential therapeutic targets for malignant lesions. Various translocations, such as those involving the anaplastic lymphoma kinase (ALK), neurotrophic tropomyosin receptor kinase 1 (NTRK1), and ...
Cecilia, Lezcano, Alexander N, Shoushtari, Charlotte, Ariyan, Travis J, Hollmann, Klaus J, Busam   +4 more
openaire   +2 more sources